Publications
Selected publications
2024
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232
A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.
Challenger, E., Dilly-Penchala, S., Hale, C., Fitzgerald, R., Reynolds, H., Chiong, J., . . . Else, L. (2024). A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.. Journal of pharmaceutical and biomedical analysis, 245, 116155. doi:10.1016/j.jpba.2024.116155
2023
Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma
Challenger, E., Penchala, S. D., Hale, C., Fitzgerald, R., Walker, L., Reynolds, H., . . . Else, L. (2023). Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 233. doi:10.1016/j.jpba.2023.115436
2022
Total and Unbound Doravirine Concentrations and Viral Suppression in CSF
Tiraboschi, J., Scevola, S., Penchala, S. D., Challenger, E., Else, L., Prieto, P., . . . Podzamczer, D. (2022). Total and Unbound Doravirine Concentrations and Viral Suppression in CSF. CLINICAL INFECTIOUS DISEASES, 74(10), 1855-1858. doi:10.1093/cid/ciab835
2021
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)
Herrera, C., Lwanga, J., Lee, M., Mantori, S., Amara, A., Else, L., . . . Fox, J. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2129-2136. doi:10.1093/jac/dkab136
2020
The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid
Penchala, S. D., Alagaratnam, J., Challenger, E., Amara, A., Else, L., Winston, A., & Khoo, S. (2020). The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. BIOMEDICAL CHROMATOGRAPHY, 34(1). doi:10.1002/bmc.4711
2019
Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment
Alagaratnam, J., Dilly-Penchala, S., Challenger, E., Else, L., Legg, K., Petersen, C., . . . Winston, A. (2019). Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 85 (pp. 1039-1040). doi:10.1111/bcp.13878
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019)
Elliot, E. R., Cerrone, M., Challenger, E., Else, L., Amara, A., Bisdomini, E., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers (vol 74, pg 149, 2019). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(5), 1466. doi:10.1093/jac/dky571
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Elliot, E. R., Cerrone, M., Else, L., Amara, A., Bisdomini, E., Khoo, S., . . . Boffito, M. (2019). Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.. The Journal of antimicrobial chemotherapy, 74(1), 149-156. doi:10.1093/jac/dky384
2018
Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk
Gini, J., Penchala, S. D., Amara, A., Challenger, E., Egan, D., Waitt, C., . . . Else, L. J. (2018). Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. BIOANALYSIS, 10(23), 1933-1945. doi:10.4155/bio-2018-0085
Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients
Molto, J., Curran, A., Miranda, C., Challenger, E., Ramon Santos, J., Ribera, E., . . . Clotet, B. (2018). Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 73(3), 732-737. doi:10.1093/jac/dkx459
2016
The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma
Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040